14.05.2013 AT0000776307
DGAP-News: Sanochemia Pharmazeutika AG: LINK HEALTHCARE OBTAINS EXTENSIVE REGIONAL RIGHTS TO SECRELUX FROM SANOCHEMIA

+ + + N E W S  S N A P S H O T + + +

DGAP-News: Sanochemia Pharmazeutika AG / Key word(s): Agreement/Product Launch Sanochemia Pharmazeutika AG: LINK HEALTHCARE OBTAINS EXTENSIVE REGIONAL RIGHTS TO SECRELUX FROM SANOCHEMIA 14.05.2013 / 08:01 --------------------------------------------------------------------- LINK HEALTHCARE OBTAINS EXTENSIVE REGIONAL RIGHTS TO SECRELUX FROM SANOCHEMIA Sydney/Pretoria/Singapore/Tokyo/Auckland: 14th May 2013 Specialist pharmaceutical and medical technologies business, LINK Healthcare ('LINK')is pleased to announce that it has signed an agreement with Sanochemia Pharmazeutika AG for regional rights to Secrelux(R), a pancreatic function diagnostic. LINK has been assigned the exclusive rights to Secrelux(R) for Australia, New-Zealand, Japan, South Africa and South East Asia excluding Korea and Philippines. LINK will give high priority to both the supply and registration of the product in these selected markets. Secrelux(R) makes possible early and clear diagnosis of pancreatic carcinomas as the precursor to targeted therapeutic intervention. Its advantage lies in the fact that it induces a marked increase in pancreatic juice secretion and bicarbonate production for a period of one to two hours which facilitates the identification of pancreatic dysfunction. Secrelux(R) is already marketed in Germany and elsewhere in Europe and internationally on a named-patient basis through Sanochemia and its subsidiaries. Executive Chairman of LINK Healthcare, John Bacon, commented: 'We are delighted to be partnering with Sanochemia to broaden the supply of this important diagnostic drug. Pancreatic cancer is reportedly the fourth most common cause of cancer-related deaths. It affects older individuals and its initial symptoms are quite non-specific. A reliable indicator of pancreatic function is an important diagnostic tool and we believe its availability will be welcomed across the region.' About Sanochemia (Germany, UK, Switzerland & USA) SANOCHEMIA, the Specialty Pharma Company, is an internationally active player with a long-standing tradition in the development and manufacture of active pharmaceutical ingredients and drugs. The Company specialises in segments of the oncology, pain management, neurodegeneration and, in particular, imaging diagnostic markets. Significant progress has already been made in the global marketing of the Company's radiological products. The marketing and sale of clinical diagnostics is undertaken by the relevant group subsidiaries in Germany, the UK, Switzerland and the USA. Activities in other markets are delegated to a network of strong cooperation partners. In the area of R&D, the focus is on the development of products to extend its in-house portfolio of human and veterinarian drugs. Through the acquisition of Alvetra und Werfft GmbH, SANOCHEMIA has succeeded in consolidating its standing in the area of veterinary medicine and also acquired additional subsidiaries in promising markets. About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore & Japan) LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK's mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa. LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of 'medicine that matters.' The range includes specialist proprietary and in-licensed products sold under the LINK Pharma, LINK Medical Technologies, EQUITY Pharmaceuticals, EQUITY Medical Technologies, HOMEMED & NOVAGEN Pharma brands. LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology. In Australia and Southern Africa the group also commercialize a unique range of medical technology products focused in the specialist areas of advanced wound care, diabetes and point of care testing. For more information about LINK Healthcare visit www.linkhealthcare.com.au FOR FURTHER INFORMATION See website for Secrelux(R) approved Product Information. Contact LINK Healthcare on 61 (2) 8401 9777 Corporate and Media Enquiries: Mr John Bacon Executive Chairman End of Corporate News --------------------------------------------------------------------- 14.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Sanochemia Pharmazeutika AG Boltzmanngasse 9a - 11 A-1091 Wien Austria Phone: +43 (1) 319 14 56-0 Fax: +43 (1) 319 14 56-344 E-mail: office@sanochemia.at Internet: www.sanochemia.at ISIN: AT0000776307, DE000A1G7JQ9 WKN: 919963, A1G7JQ Indices: General Standard Listed: Regulierter Markt in Frankfurt (General Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart; Wien (Dritter Markt (MTF) / Third Market (MTF)) End of News DGAP News-Service --------------------------------------------------------------------- 210816 14.05.2013

+ + + N E W S  S N A P S H O T + + +

.... Die vollständigen News können Sie bei [ DGAP - Medientreff abrufen ]



INVESTOR-INFORMATIONEN
©boersengefluester.de
Sanochemia Pharma
WKN Kurs in € Einschätzung
919963 1,734 Verkaufen
KGV 2018e KBV Börsenwert in Mio. €
19,27 0,48 22,32
Dividende '16 in € HV-Termin Div.-Rendite in %
0,00 22.03.2017 0,00